Difference between revisions of "Enzalutamide (Xtandi)"
(Created page with "'''In clinical trials.''' ==General information== Class/mechanism: Antiandrogen, androgen receptor signaling inhibitor (ARSI). Enzalutamide competitively inhibits testosterone ...") |
m (PeterYang moved page Enzalutamide (MDV3100) to Enzalutamide (Xtandi): FDA approval) |
(No difference)
| |
Revision as of 00:29, 1 September 2012
In clinical trials.
General information
Class/mechanism: Antiandrogen, androgen receptor signaling inhibitor (ARSI). Enzalutamide competitively inhibits testosterone from binding to the androgen receptor, interferes with translocation of the androgen receptor to the nucleus, and inhibits binding to DNA.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
- AFFIRM: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
- PREVAIL: A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)
Patient drug information
No information available.